Rosiglitazone ameliorates tissue plasminogen activator‐induced brain hemorrhage after stroke

OBJECTIVE: Delayed thrombolytic therapy with recombinant tissue plasminogen activator (tPA) may exacerbate blood‐brain barrier (BBB) breakdown after ischemic stroke and lead to catastrophic hemorrhagic transformation (HT). Rosiglitazone(RSG), a widely used antidiabetic drug that activates peroxisome...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Zhu, Zi‐Yu, Lu, Bing‐Wei, Huang, Ting‐Ting, Zhang, Yue‐Man, Zhou, Na‐Ying, Xuan, Wei, Chen, Zeng‐Ai, Wen, Da‐Xiang, Yu, Wei‐Feng, Li, Pei‐Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887660/
https://www.ncbi.nlm.nih.gov/pubmed/31756041
http://dx.doi.org/10.1111/cns.13260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887660/
https://www.ncbi.nlm.nih.gov/pubmed/31756041
http://dx.doi.org/10.1111/cns.13260

Ejemplares similares